Inhibrx Biosciences
Yahoo Finance • 2 months ago
Countdown To October: Inhibrx Awaits Ozekibart Clinical Data
(RTTNews) - Inhibrx Biosciences Inc. (INBX) has a key catalyst to watch in October involving one of its clinical drug candidates, Ozekibart. Ozekibart, formerly known as INBRX-109, is a precision-engineered, tetravalent death receptor 5 (... Full story
Yahoo Finance • 2 months ago
Inhibrx Biosciences GAAP EPS of -$1.85, revenue of $1.3M
* Inhibrx Biosciences press release [https://seekingalpha.com/pr/20200152-inhibrx-reports-second-quarter-2025-financial-results] (NASDAQ:INBX [https://seekingalpha.com/symbol/INBX]): Q2 GAAP EPS of -$1.85. * Revenue of $1.3M. * MO... Full story
Yahoo Finance • 3 months ago
Noteworthy Tuesday Option Activity: INBX, ODP, AZO
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Inhibrx Biosciences Inc (Symbol: INBX), where a total volume of 679 contracts has been traded thus far today, a contract... Full story
Yahoo Finance • 2 years ago
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
SAN DIEGO, April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registr... Full story
